Multi-Omics Mendelian Randomization Results for IBS Drug Target Discovery

A dataset of results from a druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL data to identify causal genes for irritable bowel syndrome. The analysis was conducted by Huiwen Ke and published on figshare in May 2026. It includes summary statistics from a large-scale GWAS involving 53,400 IBS cases and 433,201 controls.

Use Cases

• Prioritize candidate drug targets for IBS based on causal associations identified through Mendelian randomization.
• Validate genetic findings using colocalization analysis results likely contained in the dataset.
• Assess potential on-target adverse effects using phenome-wide association study (PheWAS) results.
• Identify existing compounds for drug repurposing via molecular docking predictions referenced in the description.

Strengths

• Analysis integrates summary statistics from a large GWAS with 53,400 cases and 433,201 controls.
• Systematic evaluation of 5,642 potential druggable protein-coding genes.
• Results include rigorous validation steps like colocalization analysis and PheWAS.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect methodological bias inherent to the specific GWAS and eQTL sources used.

Provenance

Source

figshare

Collection Method

Druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL summary statistics.

Freshness

Last updated 2026-05-18 22:02:53; freshness should be verified.